CytosinLab Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series A1

  • Latest Deal Amount
  • $13.7M

  • Investors
  • 10

CytosinLab Therapeutics General Information

Description

Developer of innovative drugs and therapies intended to treat cancer. The company develops new drugs and therapies based on epigenetics research, committing to promoting next-generation cancer treatment revolution, enabling cancel solution for patients.

Contact Information

Formerly Known As
Sailan Pharmaceutical Technology (Shenzhen) Co., Ltd.
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 2801B21, Building A, Phase I, Sunshine Science and Technology Innovation Center, Nanx
  • Nanshan Community, Nanshan District
  • Shenzhen, Guangdong 518000
  • China
+86 021
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
LOHAS & Wellness, Life Sciences, Oncology
Corporate Office
  • Room 2801B21, Building A, Phase I, Sunshine Science and Technology Innovation Center, Nanx
  • Nanshan Community, Nanshan District
  • Shenzhen, Guangdong 518000
  • China
+86 021

CytosinLab Therapeutics Timeline

2022202320242025
Financing Round

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CytosinLab Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series A1) 26-Sep-2023 $13.7M Completed Clinical Trials - General
3. Early Stage VC (Series A) 18-Nov-2021 Completed Clinical Trials - General
2. Early Stage VC 02-Mar-2021 Completed Clinical Trials - General
1. Early Stage VC 26-Apr-2020 Completed Startup
To view CytosinLab Therapeutics’s complete valuation and funding history, request access »

CytosinLab Therapeutics Patents

CytosinLab Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240376126-A1 Prmt5 inhibitor and the use thereof Pending 01-Jul-2022
AU-2023296592-A1 Class of prmt5 inhibitors and use thereof Pending 01-Jul-2022
AU-2023209975-A1 Salt crystal form and free base crystal form of kinase inhibitor Inactive 21-Jan-2022
EP-4467541-A1 Salt crystal form and free base crystal form of kinase inhibitor Inactive 21-Jan-2022
EP-4342878-A1 Arginine methyltransferase inhibitor and use thereof Pending 21-May-2021 A61K31/55
To view CytosinLab Therapeutics’s complete patent history, request access »

CytosinLab Therapeutics Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Fortune Capital Venture Capital Minority
Heda Ventures Venture Capital Minority
CDH Investments PE/Buyout Minority
Dawu Venture Capital Venture Capital Minority
Kaitai Capital Venture Capital Minority
You’re viewing 5 of 10 investors. Get the full list »

CytosinLab Therapeutics FAQs

  • When was CytosinLab Therapeutics founded?

    CytosinLab Therapeutics was founded in 2019.

  • Where is CytosinLab Therapeutics headquartered?

    CytosinLab Therapeutics is headquartered in Shenzhen, China.

  • What industry is CytosinLab Therapeutics in?

    CytosinLab Therapeutics’s primary industry is Drug Discovery.

  • Is CytosinLab Therapeutics a private or public company?

    CytosinLab Therapeutics is a Private company.

  • What is CytosinLab Therapeutics’s current revenue?

    The current revenue for CytosinLab Therapeutics is .

  • How much funding has CytosinLab Therapeutics raised over time?

    CytosinLab Therapeutics has raised $45M.

  • Who are CytosinLab Therapeutics’s investors?

    Fortune Capital, Heda Ventures, CDH Investments, Dawu Venture Capital, and Kaitai Capital are 5 of 10 investors who have invested in CytosinLab Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »